DocMorris AG (OTCPK:ZRSEF) Q2 2025 Earnings Conference Call August 19, 2025 5:00 AM ET
Company Participants
Daniel Wüest – CFO & Member of Executive Board
Walter Hess – CEO & Member of Executive Board
Conference Call Participants
Gian-Marco Werro – Zürcher Kantonalbank, Research Division
Sebastian Vogel – UBS Investment Bank, Research Division
Urs Kunz – Research Partners AG
Volker Bosse – Baader-Helvea Equity Research
Walter Hess
Good morning, everybody, and thank you for joining today’s conference call, which will be hosted by Daniel Wüest, our CFO, and me.
Let me start by giving you a quick overview of the key highlights from the first half of 2025. We delivered strong growth in our Rx business with revenues increased by 43.5%. In July, the Rx bonus was reconfirmed, which strengthens our competitive positioning in the German market. TeleClinic revenues grew by more than 150% year-on-year, while our non-Rx business in total continued to deliver steady and profitable growth of 4.4%. We also took an important step into the future by leveraging AI innovation and starting the rollout of the DocMorris Health Companion. Financially, we successfully completed the CHF 200 million capital increase with a 99% take-up rate, demonstrating strong shareholder support and confidence in our strategy. And finally, we are on track to deliver on our promises. We confirm our guidance of more than 10% revenue growth and an EBITDA in the range of minus CHF 35 million to minus CHF 55 million for the full year.
In summary, the first half of ’25 shows clearly our core business is growing steadily. Our new value drivers are scaling fast, and we are well funded and on track to deliver on our commitments.
Let’s start with the ecosystem highlights on Slide #5. And let me walk through how our company is evolving from yesterday
#DocMorris #ZRSEF #Earnings #Call #Transcript